BSEGodavari Drugs LtdHighPositive
Announced Fri, 20 Mar · 17:59 IST

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ghanshyam Jaju

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.8%1-day move
₹82.50
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+7.8+9.1+3.7+4.2+13.9+10.3+50.3+44.5+53.9+47.9
Up moveDown movePending
AI summary

Ghanshyam Jaju, a promoter of Godavari Drugs Ltd, acquired 1,80,000 convertible warrants through a preferential allotment on 18th March 2026, valued at Rs. 7,53,06,000. Before the acquisition, he held 3,50,000 equity shares (4.65% voting rights). After the allotment, his total holding — shares plus warrants — stands at 5,30,000, representing 3.46% of current voting capital and 4.24% on a fully diluted basis (assuming full conversion of warrants). The filing was made under SEBI's SAST Regulation 29(2) for disclosure of the acquisition, and a related disclosure was also filed under SEBI's Insider Trading Regulation 6(2).

Likely market impact

This is a promoter-led increase in stake, generally seen as a confidence signal from the promoter. However, the post-allotment voting stake is modest (3.46%), and the warrants are not yet shares, so any meaningful boost to promoter control will depend on future conversion.